

1. (Reiterated) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:1,
  - b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1,
  - c) a biologically active fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1, and
  - d) an immunogenic fragment of a polypeptide having an amino acid sequence of SEQ ID NO:1.
2. (Reiterated) An isolated polypeptide of claim 1, having a sequence of SEQ ID NO:1.
3. (Reiterated) An isolated polynucleotide encoding a polypeptide of claim 1.
4. (Reiterated) An isolated polynucleotide of claim 3, having a sequence of SEQ ID NO:2.
5. (Reiterated) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
6. (Reiterated) A cell transformed with a recombinant polynucleotide of claim 5.
8. (Reiterated) A method for producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
  - b) recovering the polypeptide so expressed.
9. (Reiterated) An isolated antibody which specifically binds to a polypeptide of claim 1.

10. (Reiterated) An isolated polynucleotide comprising a sequence selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:2,
- b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:2,
- c) a polynucleotide having a sequence complementary to a polynucleotide of a),
- d) a polynucleotide having a sequence complementary to a polynucleotide of b) and
- e) an RNA equivalent of a)-d).

11. (Reiterated) An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 10.

12. (Reiterated) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

13. (Reiterated) A method of claim 12, wherein the probe comprises at least 60 contiguous nucleotides.

14. (Reiterated) A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and

b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

15. (Reiterated) A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16. (Reiterated) A composition of claim 15, wherein the polypeptide has an amino acid sequence of SEQ ID NO:1.

17. (Reiterated) A method for treating a disease or condition associated with decreased expression of functional HTAP, comprising administering to a patient in need of such treatment the composition of claim 15.

18. (Reiterated) A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

44. (New) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

45. (New) A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

46. (New) A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- A1  
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.